Composition and method for treating iron deficiency anemia

• US 8,080,520 B2
• Filed: 07/20/2009
• Issued: 12/20/2011
• Est. Priority Date: 09/19/2005
• Status: Active Grant

• Current Assignee: Colorado Biolabs, Inc., Nurya Brands Incorporated
• Original Assignee: Colorado Biolabs, Inc.
• Inventors: Venkataraman, Bala, Guthrie, Michael
• Primary Examiner(s): TSAY, MARSHA M
• Application Number:
  US12/506,139
• Publication Number:
  US 20090281021A1
• Time in Patent Office: 883 Days
• Field of Search: None
• US Class Current: 514/5.4
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 38/42 Haemoglobins; Myoglobins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 7/06 Antianaemics

Abstract

A composition comprising heme iron and/or heme iron polypeptide in combination with ionic iron(s) and/or chelated iron(s). Administration of effective dosages of the present composition provides a method for treating and/or preventing iron deficiency anemia, and the physiological, biochemical, morphological, and behavioral manifestations symptomatic of same.

Claims

1. A pharmaceutical composition for treating iron deficiency or iron deficiency anemia in a human, consisting essentially of:

heme iron polypeptide; and

,

at least one chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, and iron proteinate, and combinations thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

2. A pharmaceutical composition for treating iron deficiency or iron deficiency anemia in a human, consisting essentially of:

heme iron polypeptide; and

,

iron polysaccharide,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

3. A pharmaceutical composition for treating iron deficiency or iron deficiency anemia in a human, consisting essentially of:

heme iron polypeptide;

iron polysaccharide; and

,

at least one vitamin selected from the group consisting of folic acid, vitamin B6, vitamin B12, and combinations thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

4. A pharmaceutical composition for treating iron deficiency or iron deficiency anemia in a human, consisting essentially of:

heme iron polypeptide;

at least one chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, and iron proteinate, and combinations thereof; and

,

at least one vitamin selected from the group consisting of folic acid, vitamin B6, vitamin B12, and combinations thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

5. A pharmaceutical composition for nutritional supplementation in a prenatal or lactating human female, consisting essentially of:

heme iron polypeptide;

iron polysaccharide; and

,

at least one nutrient selected from the group consisting of vitamins, minerals, and a combination thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

6. A pharmaceutical composition for nutritional supplementation in a prenatal or lactating human female, consisting essentially of:

heme iron polypeptide;

at least one chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, and iron proteinate, and combinations thereof; and

,

at least one nutrient selected from the group consisting of vitamins, minerals, and a combination thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

7. A pharmaceutical composition for nutritional supplementation in a prenatal or lactating human female, consisting essentially of:

heme iron polypeptide; and

,

iron polysaccharide,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a capsule, said capsule further including additional nutrients for the prenatal or lactating human female.

8. A pharmaceutical composition for nutritional supplementation in a prenatal or lactating human female, consisting essentially of:

heme iron polypeptide; and

,

at least one chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, and iron proteinate, and combinations thereof;

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a capsule, said capsule further including additional nutrients for the prenatal or lactating human female.